Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week ...

Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Behind Lilly's decline ...

Preview in new tab Pharmaceutical giants Eli Lilly ($LLY) and Novo Nordisk ($NVO) are engaged in a head-to-head battle to ...

The first head-to-head trial of Mounjaro and Wegovy, the weight-loss drugs, compared the effectiveness of the two leading ...